Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a world leader in specialty medicines focusing on metabolic and gastrointestinal diseases. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates that primarily target significant unmet needs in metabolic and gastrointestinal diseases.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua™ 100/33 in the U.S. and has been approved as Suliqua™ in Europe.
Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand in brief
• Glepaglutide* for short bowel syndrome (SBS)
• Dasiglucagon* for acute, severe hypoglycemia
• Dasiglucagon* for type 1 diabetes care
• Elsiglutide for chemotherapy-induced diarrhea
• A dual GLP1-GLU for obesity/type 2 diabetes
• An Undisclosed target for obesity/type 2 diabetes
We invent and develop medicines focusing on specialty metabolic and gastrointestinal diseases.
Zealand has a successful 18 year history of discovering and optimizing peptide therapeutics as novel drugs.